A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance.
We evaluated a 35-year-old diabetic male patient with type A insulin resistance, showing acanthosis nigricans. Insulin binding to the patient's Epstein-Barr-virus transformed lymphocytes was mildly reduced. The maximal insulin-stimulated autophosphorylation of the insulin receptor from the patient's transformed lymphocytes was decreased to 45% of that from the control subjects. On examination, the biological activities of insulin and insulin-like growth factor I in the patient's cultured fibroblasts, insulin sensitivity of amino isobutyric acid uptake and thymidine incorporation was decreased, but insulin-like growth factor I action was normal. The sequence analysis of amplified genomic DNA revealed that the patient was heterozygous for a mutation substituting Leu for Trp at codon 1193 in exon 20 of the insulin receptor gene. The patient's mother and sister were also heterozygous for a mutation in the insulin receptor gene that substituted Leu for Trp1193 in the beta subunit of the receptor. Therefore, the mutation causes insulin resistance in a dominant fashion. They were less hyperglycaemic and more hyperinsulinaemic than the proband after glucose loading. The mother had diabetes mellitus but did not show acanthosis nigricans, while the sister did not have diabetes and showed acanthosis nigricans. These results suggest that this mutation causes defective tyrosine kinase activity of the insulin receptor, which results in insulin resistance. Insulin action and phenotypic appearance may be mediated by different factors.
Iwanishi
M
M
First Department of Medicine, Toyama Medical and Pharmaceutical University, Japan.
Haruta
T
T
Takata
Y
Y
Ishibashi
O
O
Sasaoka
T
T
Egawa
K
K
Imamura
T
T
Naitou
K
K
Itazu
T
T
Kobayashi
M
M
D000328:Adult; D000483:Alleles; D000595:Amino Acid Sequence; D000621:Aminoisobutyric Acids / Q000378:metabolism; D001483:Base Sequence; D001692:Biological Transport / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002461:Cell Line, Transformed; D002478:Cells, Cultured; D003241:Consanguinity; D004247:DNA / Q000235:genetics; D005091:Exons; D005260:Female; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D007328:Insulin / Q000378:metabolism / Q000494:pharmacology; D007333:Insulin Resistance / Q000235:genetics*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D007930:Leucine; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides; D010375:Pedigree; D017354:Point Mutation; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011972:Receptor, Insulin / Q000235:genetics* / Q000378:metabolism; D012016:Reference Values; D013577:Syndrome; D013936:Thymidine / Q000378:metabolism; D014364:Tryptophan
D000621:Aminoisobutyric Acids; D001786:Blood Glucose; D007328:Insulin; D009838:Oligodeoxyribonucleotides; C100049:2-aminoisobutyric acid; D007334:Insulin-Like Growth Factor I; D014364:Tryptophan; D004247:DNA; D011505:Protein-Tyrosine Kinases; D011972:Receptor, Insulin; D007930:Leucine; D013936:Thymidine